Biomedical subjects

I Boos

Publications and source records attributed to I Boos.

7 recordsLinked to original sources

PubMed2000

Flexible tantalum stents for the treatment of renovascular hypertension: a 10-year experience.

The aim of this study was to determine long-term success of flexible tantalum stents for the treatment of ostial and truncal renal artery stenosis. Since 1989, flexible tantalum stents (type Strecker) were implanted in 34 patients (36 arteries, 25 ostial lesions, 11 truncal lesions) with uncontrollable renovascular hypertension, 9 of them in association with renal insufficiency. Stents were placed unilaterally in 32 patients, and bilaterally in 2 patients for the treatment of renal artery stenosis. Thirty-five of 36 lesions were atherosclerotic, including 5 recurrencies after previous percutaneous transluminal renal angioplasty (PTRA). One patient had Takayasu arteritis. Stents were implanted after unsuccessful PTRA of 11 truncal and 23 ostial lesions, and as a primary procedure in 2 ostial lesions. Follow-up examinations included blood pressure measurement, determination of serum creatinine level, color duplex sonography, or angiography. The technical success rate was 92%. Technical failure included incorrect stent placement (1 of 36 lesions, 2.8 % ), and stent dislocation (2 of 36 lesions, 5.6 %), and two stents were retrieved percutaneously. In one case of Takayasu arteritis, residual stenosis of 40% was observed. After technically successful stent placement, 77% of patients became normotensive with or without medication. In the remaining patients there was partial improvement with blood pressure between 140 and 180 mmHg. Renal function improved in 76% of patients (completely in 3 of 8, 38%; and partially in 3 of 8, 38%). Primary patency rate including all stented lesions and initial technical failures was 82.4% +/- 6.8 (1 year) and 82.4% +/- 9.2 (3 years). After technically successful stent placement, patency rates were 89.9 +/- 5.6% (1 year), and 89.9 +/- 7.6% (3 years). For ostial lesions, primary patency rate was 87.9 +/- 6.7% (1 year) and 87.9 +/- 9.2% (3 years). Placement of flexible tantalum stents in renal arteries is technically demanding, especially in ostial lesions. Once placed successfully stent patency rate is excellent.

Aged↗

PubMed1999

[Dose-dependent decrease of the rate of restenosis of stents in peripheral vessels with reviparin].

PURPOSE: In clinical prospective trials, we examined the effect of the low molecular weight heparin (lmwh) reviparin on restenosis rate after Strecker stent implantation in femoral popliteal arteries. MATERIALS AND METHODS: 62 patients were treated between 1992 and 1998. Patients received reviparin, 3500 IU, prior to stent implantation followed by 7500 IU for 24 h (i.v.) and 2 x 1750 IU/day s.c. over three weeks (n = 12) or 10,500 IU for 24 h (i.v.) and 2 x 3500 IU/day s.c. over 3 1/2 weeks (n = 50). Follow-up parameters were clinical symptoms, ankle-brachial index, color Doppler flow duplex sonography, and DSA. RESULTS: Three thrombotic occlusions and three stenoses were observed in the low-dose group. Raising the dose resulted in neither thrombotic nor other events within the first three months. Seven stenoses occurred afterwards up to the 7th month. The complication rate was low: one moderate hematoma and one puncture aneurysm. Primary patency rate was 88% and 80% for one and two years, respectively. This is significantly better than the primary patency rates for patients receiving low-dose lmwh (p < 0.005) or unfractionated heparin (p < 0.05). CONCLUSIONS: Hence, high-dose administration of the lmwh reviparin lowers the restenosis rate after stent implantation in femoropopliteal arteries.

Aged↗

PubMed1995

Malignant duodenal stenosis: palliation with peroral implantation of a self-expanding nitinol stent.

The authors implanted a duodenal stent in a woman with a high-grade duodenal stenosis due to inoperable tumor compression. A flexible self-expanding knitted nitinol stent that conformed to the shape of the duodenum was introduced orally to keep the duodenal passage patent. After stent implantation, repeated vomiting stopped and the patient was able to eat and drink. This technique resolved the patient's duodenal stenosis.

Adenocarcinoma↗

PubMed1994

Current status of the Strecker stent.

Knitted flexible tantalum stents proved to be a valuable adjunct to percutaneous transluminal angiplasty (PTA) in the case of insufficient PTA results, and their use was established in the distal aorta, the iliac, the femoro-popliteal, the renal, and the coronary arteries. Recently, long arterial occlusions were defined as new indications for primary stenting; stent indications were further extended to the subclavian, the carotid, and the splanchnic arteries. Due to higher incidence of acute and late complications after stent treatment of small diameter arteries, patients have to be selected thoroughly. Newly designed drug-releasing stents tested in animal experiments promised to be suitable to diminish the incidence of late restenosis due to intinal hyperplasia, thus providing better long-term patency.

Angioplasty, Balloon↗

PubMed1990

[Peroxidase activity of urinary cell elements, leucocyturia and urinary tract infection].

Peroxidase activity determination of urinary formed elements is proposed as a new leucocyturia detection method. Enzymatic activity is evidenced by hydrogen peroxide 0.54 mM in Trinder reagent. The reaction can be performed in filtrative microplate or in standard microplate. Results are formulated semi-quantitatively or using arbitrary units (UA/ml) respectively. Reproducibility of the peroxidase activity assay (n = 31, m = 754 UA/ml, CV = 6.8%) is higher than microscopic evaluation methods (direct microscopic examination: n = 31, m = 3, CV = 66%; standard sediment method: n = 31, m = 7, CV = 71%). Urine conservation is suitable during about 20 hours at 4 degrees C. In case of microscopic hematuria (less than 1.5 x 10(6) red blood cells/ml) only few interference was observed. On the other hand, macroscopic hematuria may be inhibitory for the enzymatic reaction. Peroxidase activity determination, microscopic leucocyte count and bacterial numeration were performed on 2,004, 1,589 and 1,709 urine samples, respectively. The low correlation between peroxidase activity and microscopic leucocyte count is discussed. This new enzymatic method contributes to detect urine samples with significant bacteriuria (greater than or equal to 10(5) UFC/ml): about 90 p. cent sensitivity and 95 p. cent negative predictive value.

Erythrocytes↗

PubMedDate not supplied

Effect on intimal hyperplasia of dexamethasone released from coated metal stents compared with non-coated stents in canine femoral arteries.

PURPOSE: Polymer-coated, dexamethasone (DXM)-releasing stents were tested in order to assess the efficacy of DXM released locally for the prevention of stent restenosis due to intimal hyperplasia. METHODS: Strecker stents coated with a biodegradable membrane containing DXM were implanted percutaneously into the femoral artery in 14 dogs. The contralateral artery received a conventional non-coated stent serving as control. The drugs are eluted by degradation of the carrier membrane. Follow-up intraarterial digital subtraction angiography (DSA) was obtained at 3, 6, 9, 12, and 24 weeks with subsequent autopsy. Specimens for gross and microscopic pathology were obtained and histomorphometry was performed. RESULTS: Four of 14 DXM-coated stents showed thrombotic occlusion within the first 3 weeks; ten DXM-coated stents remained patent. At follow-up DSA, DXM-coated stents showed a significantly wider lumen than the non-coated stents. At morphometry there was less intimal hyperplasia over DXM-coated stents than over non-coated stents (p < 0.05). CONCLUSION: DXM-coated stents reduce neointimal hyperplasia in dogs when compared with non-coated stents.

Angiography↗

PubMedDate not supplied

Nitinol esophageal stents: new designs and clinical indications.

PURPOSE: To evaluate the clinical use of covered and noncovered, knitted nitinol stents in patients presenting new stent indications. METHODS: Self-expandable, knitted nitinol stents were implanted in four patients for treatment of dysphagia. In two patients who had malignant strictures and had esophago-respiratory fistulae and in one patient with an esophagocutaneous fistula, polytetrafluoroethylene (PTFE)-covered stents were implanted. One patient received a noncovered stent, but a retrograde approach through a percutaneous endoscopic gastrostomy (PEG) fistula had to be chosen for recanalization of an esophageal occlusion. Two patients received stents for treatment of benign strictures. RESULTS: Recanalization of the stricture and stent implantation were performed under fluoroscopic control without any procedure-related morbidity or mortality. Dysphagia improved in all patients and the esophageal fistulae could be sealed off by covered stents. During a maximum follow-up of 18 months, there was no stent migration or esophageal perforation. Complications observed were stent stenosis due to food impaction (1/4) and benign stent stenosis (2/2). Most complications could be treated by the interventional radiologist. CONCLUSION: Self-expandable, covered Nitinol stents provide an option for the treatment of dysphagia combined with esophageal fistulae. In combination with interventional radiology techniques, even complex strictures are accessible. For benign strictures, the value of stent treatment has not yet been proven.

Adult↗